By: ASL Anemia is one of the most common co morbid diseases in patients with symptomatic chronic heart failure and is associated with poor quality of life. Besides anemia in chronic heart failure is a strong independent risk factor in increasing morbidity and mortality. Pathophysiology of anemia in chronic heart failure is the deficiency of absolute or relative deficiency of erythropoietin as well and iron deficiency. So the estimated provision of erythropoietin as an agent in stimulate erythropoiesis is a rational thing. A meta-analysis conducted to see the effects of anemia with erythropoietin therapy on cardiac function in patients with chronic heart failure. By objective measuring is ventricular left ejection fraction, heart failure according to NYHA class, exercise duration, distance walk during six minutes, the volume of O2 peak, levels of BNP, the Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, Kansas City Cardiomyopathy Questionnaire (KCCQ) and Patient's Global Assessment (PGA). Of the 116 articles that have traced, there are seven articles that met the inclusion criteria of the years 2001 to 2008 with a total of 678 patients where 371 patients receiving erythropoietin therapy and 307 patients as the control group. From the results of this meta-analysis, three articles conclude that there is improvement in left ventricular ejection fraction when anemia was corrected (p = 0.0007). Quality of life of patients as measured by the PGA also showed improvement after treatment of anemia (OR 2.55 p = 0.05). NYHA class, exercise duration, distance walked during six minutes, the volume of O 2 peak, levels of BNP and changes in KCCQ score also showed improvement in the group of patients post-therapy with erythropoietin therapy. So it can be concluded from this study that anemia therapy with erythropoietin proved to significantly improve cardiac function in patients with chronic heart failure. Source : www.kalbe.co.id